Dr. Reddy’s Laboratories Ltd. (BSE: 500124 NSE: DRREDDY NYSE: RDY along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Ziprasidone Mesylate for Injection 20 mg (base)/mL Single-dose Vials the therapeutic generic equivalent of Geodon® (ziprasidone mesylate) Injection 20 mg/mL approved by the U.S. Food and Drug Administration (USFDA).
“We’re pleased to bring the first generic of Ziprasidone Mesylate for Injection to market for patients who will benefit from access to affordable medicine. With every new product launch we believe we are making healthcare more affordable by delivering value to the pharmacy” explains Marc Kikuchi Chief Executive Officer North America Generics Dr. Reddy’s Laboratories. “This is a great addition to our injectable offering in the U.S. market as we continue to augment our portfolio and drive growth within the hospital segment.”
The Geodon® brand had U.S. sales of approximately $21.8 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health*.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Ziprasidone mesylate for injection is not approved for the treatment of patients with Dementia-Related Psychosis.
Geodon® is a trademark of Pfizer
*IQIA Retail and Non-Retail MAT January 2020